Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) JSFK (Jurnal Sains Farmasi & Klinis)
Rudi Safarudin
Universitas Tadulako
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
PROFIL PENGGUNAAN OBAT PADA PASIEN GOUT DAN HIPERURISEMIA DI RSU ANUTAPURA PALU Nur Fadhilatu Rahmah; Alwiyah Mukaddas; Safarudin Safarudin
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) Vol. 2 No. 2 (2016): (October 2016)
Publisher : Universitas Tadulako

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (159.896 KB) | DOI: 10.22487/j24428744.2016.v2.i2.5985

Abstract

Gout is a type of inflammatory arthritis triggered by the crystallization of uric acid within the joints and is often associated with hyperuricemia. Hyperuricemia is a condition with high blood uric acid levels (above normal). This study aimed to describe drug use profile of gout and hyperuricemia inpatients in Anutapura Hospital, Palu. This is a descriptive study of which samples taken retrospectively. The result showed that the characteristic of 32 inpatients are as follows : most (71.86%) of them are male, 71.86% aged 18-59 years old, 21.86% had high school educational degree, and 21.86% are civil servants. As many as 32.18% of the patients had pain clinical manifestation, 93.75% were diagnosed with gout and 90.63% had high uric acid levels. Patients with amount variation of 5 to 8 drugs were 78.13% dominated by oral anti-inflamatory class of drug therapy (46.3%), with oral NSAIDs as much as 17.71% such as meloxicam (9.71%). Most patients got tablets (50%) and the drugs were found 71.43% in oral route of administration. Keywords : Gout, Hyperuricemia, Anti-inflamatory, NSAIDs.
Identifikasi Drug Related Problems (DRPs) Pada Pasien Pediatri Pneumonia Komunitas di Instalasi Rawat Inap RSD Madani Provinsi Sulawesi Tengah: Identification of Drug Related Problems In Pediatric Patients With Community Acquired Pneumonia at Madani Hospital Central Sulawesi Putu Maharani Ajeng Astiti; Alwiyah Mukaddas; Safarudin Atho Illah
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal) Vol. 3 No. 1 (2017): (March 2017)
Publisher : Universitas Tadulako

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (223.265 KB) | DOI: 10.22487/j24428744.2017.v3.i1.8140

Abstract

Drug Related Problems (DRPs) are events or circumstances involving drug therapy that actually or potentially interfere with desired health outcomes. DRPs may occur in the treatment of various diseases such as community acquired pneumonia (CAP). This study aims to determine the percentage of DRPs in pediatric inpatients with CAP. This is a descriptive and observational study design with prospective data conducted in November 2015 until February 2016 at Madani Hospital, Central Sulawesi. The results obtained from 28 patients showed that incidences of DRPs categories of inappropriate drug is 1 event (1,7%), inappropriate drug combination 35 events (58,3%), drugs dose too low 18 events (30%), drugs dose too high 6 events (10%), and no indication for drug 0 event (0%).
Review: Perbandingan antara Standard Half-Life (SHL) dan Extended Half-Life (EHL) Replacement Therapy berbasis Real-World Evidence (RWE) Agriawan Sudirman; Suharjono Suharjono; Ahmad Nasir; Rudi Safarudin
Jurnal Sains Farmasi & Klinis Vol 9, No 3 (2022): J Sains Farm Klin 9(3), Desember 2022
Publisher : Fakultas Farmasi Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jsfk.9.3.221-226.2022

Abstract

Hemophilia is a common hereditary coagulation blood disorder due to the deficiency activity of clotting factors. Hemophilia is divided into two, namely hemophilia A and hemophilia B. Among all treatments, standard half-life (SHL) and extended half-life (EHL) factor replacement products are the most commonly used. This study aimed to review real-world evidence on the comparison of SHL and EHL. A literature search was conducted in PubMed and google scholar published from 2017 to 2021. There were 10 articles that met the criteria. Based on the synthesis results, the total proportion of patients using EHL factor concentrates for both on‐demand and prophylactic factor replacement therapy increased. Recent evidence reveals that EHL may reduce the number of infusions, increase factor trough levels, and substantially decrease the annual bleeding rate. Efficacy-wise, EHLs unquestionably have better performances than SHLs; however, the EHL products seem to be too expensive to be utilized as the primary standard of care for hemophilia. However, the economic aspect of the replacement factor switching still required more in-depth studies.
Co-Authors Agriawan Sudirman Ahmad Nasir Alwiyah Mukaddas Nur Fadhilatu Rahmah Putu Maharani Ajeng Astiti Suharjono, Suharjono